[Therapeutic use of alpha interferon in metastasizing malignant melanoma, disseminated Kaposi sarcoma and severe Behcet disease]

Important note: Information in this article was accurate in 1988. The state of the art may have changed since the publication date.

[Therapeutic use of alpha interferon in metastasizing malignant melanoma, disseminated Kaposi sarcoma and severe Behcet disease]

Hautarzt. 1987 Aug;38(8):453-60. Unique Identifier : AIDSLINE MED/88006808
Stadler R; Bratzke B; Orfanos CE; Universitats-Hautklinik und Poliklinik, Klinikum Steglitz,; Freien Universitat Berlin.

Abstract: Three types of human interferons (IFNs) are differentiated: alpha-interferon (with about 20 subtypes), beta-interferon, and gamma-interferon. In addition to their antiviral properties, these IFN types exert numerous other biological effects, which are increasingly exploited for therapeutic purposes. From 1982 to 1985 long-term recombinant alpha 1-interferon (rIFN-alpha A) was administered systemically in 39 patients with various severe dermatoses. In this study we report our preliminary experiences with systemic administration of rIFN-alpha A in malignant melanoma (MM, 9 patients), in disseminated Kaposi's sarcoma (KS, 8 patients), and in severe Behcet's disease (2 patients). In metastatic MM (clinical stage IV) the result was only moderate; the administration of IFN in earlier stages, for instance as a postoperative adjuvant therapy, appears more promising. In disseminated KS with acquired immune deficiency syndrome (AIDS) our experience was encouraging. In 7/8 patients the general condition was stabilized and partial remission of skin lesions was observed. In Behcet's disease both patients had good or excellent responses to IFN treatment. The side effects of systemic rIFN-alpha A were moderate, dose-dependent, and tolerable.

Keywords: Acquired Immunodeficiency Syndrome/COMPLICATIONS Adult Aged Behcet's Syndrome/THERAPY Combined Modality Therapy English Abstract Female Human Interferon Type I/*THERAPEUTIC USE Male Melanoma/*THERAPY Middle Age Neoplasm Metastasis Neoplasms, Multiple Primary/*THERAPY Recombinant Proteins/*THERAPEUTIC USE Sarcoma, Kaposi's/*THERAPY Skin Neoplasms/*THERAPY JOURNAL ARTICLE

880130
M8810336

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1988. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1988. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .